SCHEMBL9975606

SCHEMBL9975606

CC(=O)c1ccc(N(C)c2csc(-c3ccccc3)n2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.47
RAB9A P51151 7/20 0.47
NPC1 O15118 6/20 0.47
KDM4E B2RXH2 2/20 0.47
MAPT P10636 4/20 0.45
HDAC1 Q13547 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
USP2 O75604 1/20 0.41
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
NFKB1 P19838 1/20 0.41
MAPK1 P28482 1/20 0.41
MMP13 P45452 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9975611 0.84 SREBF2 (0.46) SMN1; SMN2RAB9ANPC1KDM4EMAPT
SCHEMBL9975609 0.83 HPGD (0.48) SMN1; SMN2RAB9ANPC1KDM4EMAPT
SCHEMBL8238620 0.83 RARA (0.54) SMN1; SMN2RAB9ANPC1MAPTMEN1
SCHEMBL8239215 0.82 HPGD (0.51) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL9975610 0.82 SREBF2 (0.56) SMN1; SMN2RAB9ANPC1KDM4EMAPT
SCHEMBL8239699 0.81 MAPT (0.46) SMN1; SMN2RAB9ANPC1KDM4EMAPT
SCHEMBL8233212 0.80 HPGD (0.50) SMN1; SMN2RAB9ANPC1TP53HPGD
SCHEMBL9975607 0.78 CNR2 (0.42) SMN1; SMN2RAB9ANPC1KDM4EMAPT
SCHEMBL9975602 0.78 MAPT (0.49) SMN1; SMN2RAB9ANPC1KDM4EMAPT
SCHEMBL11507427 0.77 HDAC1 (0.48) SMN1; SMN2RAB9ANPC1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8394798-B2 Compositions and methods for inducing neuronal differentiation THE SCRIPPS RESEARCH INSTITUTE (US) 2013-03-12 US disclosed
US-20120157457-A1 COMPOSITIONS AND METHODS FOR INDUCING NEURONAL DIFFERENTIATION THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157457-A1 COMPOSITIONS AND METHODS FOR INDUCING NEURONAL DIFFERENTIATION CHAT, DCX, GAP43 SMN1; SMN2 115/4885RAB9A 2310/4885NPC1 1361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.